HALOZYME THERAPEUTICS, INC. SAN DIEGO, Feb. 17, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the manuscript "Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy" has been published in Molecular Cancer Therapeutics (February 2015 14:523-532). The paper expands on previously reported data in a poster presentation at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium in San Francisco, CA. The manuscript was written and funded by Halozyme Therapeutics, Inc.
"This paper provides a comprehensive description of the preclinical characterization of how investigational PEGPH20 has the potential to enhance the anti-cancer activity of the accompanying immunotherapy (trastuzumab and immune cells) in a high hyaluronan (HA) tumor model," stated H. Michael Shepard, Ph.D., Vice President and Chief Scientific Officer. "These data suggest that PEGPH20 not only has the potential to enhance the access of drug into an HA-high tumor by reducing the pressure inside of the tumor, but also breaks the physical barrier on the cancer cell surface, thus potentially exposing the cancer cells and allowing the immune system to attack the malignant cells more efficiently."
Publication Summary:
- PEGPH20 enhances HA-high breast cancer cell killing by trastuzumab and natural killer (NK) cells in vitro.
- Upon PEGPH20 application, synapse formation between immune and cancer cells occurs and promotes the killing capacity of NK cells.
- PEGPH20, by removing HA from the cancer cell surface, potentially allows greater contact of NK cells to tumor cells, a key process involved in antibody-dependent cell-mediated cytotoxicity of cancer cells.
About PEGPH20
PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under clinical development for the systemic treatment of tumors that accumulate hyaluronan.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, our investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning future actions relating to the development of PEGPH20) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected developments in clinical trials (including potential additional safety events), unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2014.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Susan Neath Francis
212-301-7182
sfrancis@w2ogroup.com
Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/halozyme-announces-preclinical-study-results-of-pegph20-published-in-molecular-cancer-therapeutics-300036609.html
SOURCE Halozyme Therapeutics, Inc.
|
distributed by
|
